Amundi’s CorMedix CRMD Stock Holding History

Amundi’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123K	Sell	15,642 -3,737	-19%	-$29.5K	﹤0.01%	2017
2026 Q1	$132K	Buy	+19,379	New	+$143K	﹤0.01%	1938

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Amundi's CRMD Position: Q2 2026 in Review

Amundi reduced its CorMedix (CRMD) stake by 19% in Q2 2026, selling an estimated $29.5K and leaving 15,642 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Amundi first reported a position in CRMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $132K in Q1 2026. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Amundi held 15,642 shares of CorMedix worth $123K as of Q2 2026.
Amundi sold 3,737 CorMedix shares in Q2 2026, an estimated $29.5K.
CorMedix made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #2017 holding.
Amundi first reported a position in CorMedix in Q1 2026 and has held it in 2 quarters since.
Amundi's CorMedix position peaked at $132K in Q1 2026.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.